Order results by:
| Issue | Title | |
| Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
| "... is discussed. Approaches to antiplatelet agent choice according to pharmacogenetic CYP2C19 testing, as well ..." | ||
| Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
| A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
| "... Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization ..." | ||
| Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
| A. N. Meshkov | ||
| "... in atherosclerosis progression and thrombotic complications. That is why antiplatelet therapy is a necessary element ..." | ||
| Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
| M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
| "... CYP2C19 – omeprazole, accompanied by a decrease in the effectiveness of antiplatelet therapy, was also ..." | ||
| Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
| S. J. Martsevich | ||
| Vol 17, No 5 (2021) | Pharmacogenetic Aspects of Postoperative Anesthesia with Ketoprofen in Cardiac Surgery Patients | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Z. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. А. Grishina, D. A. Sychev | ||
| "... Aim. Evaluation of the effect of polymorphisms of the CYP2D6, CYP2C8 genes on the efficacy ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| "... anticoagulants choice on the basis of pharmacogenetic testing as well as indications for this approach ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... metabolized by CYP3A4 with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19 and CYP2J2 isoenzymes ..." | ||
| Vol 3, No 2 (2007) | VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY | Abstract similar documents |
| D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes | ||
| "... of polymorphisms of genes of their biotransformation (CYP2C9) and molecule-targets (VKORC1). This created basis ..." | ||
| Vol 15, No 3 (2019) | Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population | Abstract similar documents |
| K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev | ||
| "... the importance of studying the most clinically valid and clinically useful pharmacogenetic markers (CYP2C19, CYP2 ..." | ||
| Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
| "... Aim. Carriership of CYP2C19*2 allelic variant and reduced CYP3A4 activity can affect the formation ..." | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... Aim. To search for new pharmacogenetic biomarkers of bleeding risk in patients taking rivaroxaban ..." | ||
| Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
| E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
| "... as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often ..." | ||
| Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
| "... Background. Carriership of CYP4F2*3 (rs2108622, Val433Met) allelic variant can affect antiplatelet ..." | ||
| Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
| "... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| Vol 16, No 2 (2020) | Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev | ||
| "... of CYP2C9 and VKORC1 genes mutations were determined at the initial examination. These indicators were ..." | ||
| Vol 10, No 6 (2014) | PHARMACOGENETIC TESTING OPPORTUNITIES IN CARDIOLOGY BASED ON EXOME SEQUENCING | Abstract similar documents |
| N. V. Shcherbakova, A. I. Ershova, A. A. Suvorova, E. Y. Hlebus, A. N. Meshkov, S. A. Boytsov | ||
| "... can be obtained by pharmacogenetic testing using data exome sequencing in patients with cardiac ..." | ||
| Vol 13, No 2 (2017) | SECONDARY PREVENTION IN PATIENTS AFTER MYOCARDIAL INFARCTION AT AMBULATORY SPECIALIZED CARDIOLOGY INSTITUTION (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. B. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, D. A. Dimitrova | ||
| "... recommended for patients with a history of myocardial infarction (antiplatelets – 91.76%, beta-blockers – 83 ..." | ||
| Vol 19, No 5 (2023) | Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease | Abstract similar documents |
| N. A. Shatalova, D. A. Sychev, K. B. Mirzaev, A. I. Kochetkov, E. Yu. Ebzeeva, V. B. Dashabylova, P. O. Bochkov, S. N. Tuchkova, S. V. Glagolev | ||
| "... 1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual ..." | ||
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... apixaban together with a CYP3A4/P-gp inhibitor were 3.5 times more likely to have hemorrhagic complications ..." | ||
| Vol 14, No 1 (2018) | NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| Ju. P. Skirdenko, N. A. Nikolayev | ||
| "... , polymorphism of genes CYP2C9 and VKORC1 and the structure of food preferences. Results. Persons ..." | ||
| Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
| N. В. Perepech, A. V. Tregubov | ||
| "... Aim. To study the doctors' opinions on the main aspects of antiplatelet agents use, and to test ..." | ||
| Vol 17, No 1 (2021) | Pharmacogenetics as a Way for Personalizing Diuretic Therapy: Focus on Torasemide | Abstract similar documents |
| N. M. Gafurova, E. V. Shikh, O. D. Ostroumova | ||
| "... of a patient. Pharmacogenetics of torasemide may be of significant importance for pharmacokinetics ..." | ||
| Vol 18, No 4 (2022) | The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome | Abstract similar documents |
| V. A. Shumkov, K. A. Zagorodnikova, S. A. Boldueva, A. A. Murzina | ||
| "... Aim. The aim of this work was to study the occurrence of the rs776746 allelic variant of the CYP3A ..." | ||
| Vol 17, No 4 (2021) | Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery | Abstract similar documents |
| T. E. Morozova, D. A. Shatsky, N. V. Shikh, E. V. Shikh, T. B. Andrushchyshina, M. V. Lukina, A. A. Kachanova, Zh. A. Sozaeva, G. N. Shuev, N. P. Denisenko, E. A. Grishina, D. A. Sychev | ||
| "... therapy in patients with CYP2C9*2 (430C>T) rs179985 and CYP2C9*3 (1075A>C) rs1057910 gene polymorphisms ..." | ||
| Vol 4, No 2 (2008) | EFFECT OF GENES SLCO1B1 AND MDR1 POLYMORPHISM ON ATORVASTATIN PHARMACOKINETICS AND PHARMACODYNAMICS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: RESULTS OF PILOT PHARMACOGENETICS STUDY | Abstract similar documents |
| A. V. Semenov, D. A. Sichev, V. G. Kukes | ||
| Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
| N. B. Perepech | ||
| "... of patients with chronic IHD are also presented. The main attention is paid to antiplatelet agents ..." | ||
| Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
| S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
| "... the need of dual antiplatelet agents therapy. ..." | ||
| Vol 17, No 1 (2021) | Pharmacokinetics and Pharmacogenetics of Dabigatran | Abstract similar documents |
| A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder | ||
| "... , pharmacokinetics and pharmacogenetics of dabigatran are variable. This can affect both effectiveness and safety ..." | ||
| Vol 9, No 6 (2013) | APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY | Abstract similar documents |
| D. A. Sychev, G. N. Shuev, A. B. Prokofiev | ||
| "... determination on the basis of pharmacogenetic testing is discussed. Indications for the use of this approach ..." | ||
| Vol 8, No 4 (2012) | ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE | Abstract similar documents |
| S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin | ||
| "... Alternative approaches to the use of two component antiplatelet therapy in patients with acute ..." | ||
| Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
| I. A. Latfullin, A. A. Podolskaya | ||
| "... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as acetylsalicylic acid ..." | ||
| Vol 14, No 1 (2018) | PHARMACOGENETIC STUDIES IN CARDIOLOGY: THE PROBLEM OF "DEPTH" OF THE ISSUE STUDY AND THE CORRECTNESS OF USING "GENETIC" TERMS | Abstract similar documents |
| D. A. Sychev, G. I. Lifshits | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... Aim. The aim of our study was to investigate the influence of polymorphic markers of CYP3A4*22 CYP ..." | ||
| Vol 20, No 3 (2024) | Use of glycoprotein IIb/IIIa inhibitors in myocardial infarction in the Russian Federation, according to the Russian Registry of Acute Myocardial Infarction REGION-IM | Abstract similar documents |
| N. S. Kostritca, R. M. Rabinovich, R. M. Shakhnovich, I. S. Yavelov, R. G. Gulyan, Yu. K. Rytova, S. N. Tereschenko, A. D. Erlikh, D. V. Pevzner | ||
| Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
| I. S. Yavelov | ||
| "... Prerequisites for the prolonged dual antiplatelet therapy after myocardial infarction are presented ..." | ||
| Vol 19, No 3 (2023) | Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report | Abstract similar documents |
| A. A. Kudriavtseva, E. V. Kolpachkova, Z. A. Gebekova, T. A. Sadulaeva, A. A. Sokolova, D. A. Napalkov | ||
| "... concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed ..." | ||
| Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
| "... and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel). Material and methods. 98 patients ..." | ||
| Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
| K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
| "... value had 71 (68.3%) patients, HAS-BLED≥3 – 33 (31.7%). Only one antiplatelet agent was prescribed to 4 ..." | ||
| Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
| E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
| "... ,007 in G2). Conclusion. Resistance to antiplatelet drugs is observed more often in patients with DM2 ..." | ||
| Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
| E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
| "... antiplatelet therapy with acetyl salicylic acid and clopidogrel. Numerous clinical characteristics ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... genes with the development of resistance to antiplatelet drugs in CHD patients. Material and Methods ..." | ||
| Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
| S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
| "... Aim. To compare the antiplatelet efficacy of the original and generic enterosoluble tableted ..." | ||
| Vol 5, No 6 (2009) | ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS | Abstract similar documents |
| N. A. Dmitrieva, S. N. Tolpygina | ||
| Vol 6, No 1 (2010) | ANTITHROMBOTIC THERAPY AT AN ATRIAL FIBRILLATION: OLD PROBLEMS AND NEW SOLUTIONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... The problem of antiplatelet drug choice in patients with atrial fibrillation is discussed. Authors ..." | ||
| Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
| M. Yu. Gilyarov, Е. V. Konstantinova | ||
| "... atherosclerotic plaque. The use of acetylsalicylic acid with addition of the second antiplatelet agent, so-called ..." | ||
| Vol 7, No 1 (2011) | NEW ANTIPLATELET DRUGS (PART 1) | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern atherosclerosis therapy. The difficulties ..." | ||
| Vol 7, No 5 (2011) | NEW ANTIPLATELET DRUGS. PART 2 | Abstract similar documents |
| A. B. Sumarokov | ||
| "... Antiplatelet agents are a necessary component of modern therapy of atherosclerosis ..." | ||
| Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
| K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
| "... antiplatelet drugs (acetylsalicylic acid and clopidogrel) and heparin. There were not any reasons ..." | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... Aim. Study of the association of polymorphic variants of CYP2C19 (G681A), P2RY12 (H1/H2), ITGB3 (T ..." | ||
| Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
| O. V. Gaisenok | ||
| "... Current issues of atherothrombosis prevention and treatment optimization with antiplatelet therapy ..." | ||
| Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
| I. N. Bokarev, L. V. Popova | ||
| "... is highlighted. ASA modes of action and its position among the modern antiplatelet agents are considered ..." | ||
| Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
| "... schemes and the preferred doses of statins and antiplatelet agents depending on the localization ..." | ||
| Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
| N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
| "... to obtain the necessary information on the issue of control of antiplatelet therapy. The review brings ..." | ||
| Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
| "... Aim. To evaluate an adequacy of dual antiplatelet therapy (DAPT) in patients with acute coronary ..." | ||
| Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
| "... to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have ..." | ||
| Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
| E. N. Dankovtseva, D. A. Zateyshchikov | ||
| Vol 9, No 6 (2013) | ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? | Abstract similar documents |
| Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein | ||
| "... heart disease after percutaneous coronary intervention and its contribution to antiplatelet therapy ..." | ||
| Vol 5, No 6 (2009) | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky | ||
| Vol 7, No 3 (2011) | STROKE PREVENTION IN INTERNIST PRACTICE | Abstract similar documents |
| D. A. Napalkov, A. V. Zhilenko | ||
| "... требованиями современных рекомендаций. Современная фармакотерапия включает антиагреганты или антикоагулянты ..." | ||
| Vol 8, No 6 (2012) | THE LIS STUDY (LYUBERTSY STUDY ON MORTALITY RATE IN PATIENTS AFTER ACUTE MYOCARDIAL INFARCTION). EVALUATION OF DRUG THERAPY. PART 2. INFLUENCE OF PREVIOUS DRUG TREATMENT ON LONG-TERM LIFE PROGNOSIS | Abstract similar documents |
| S. Yu. Martsevich, M. L. Gynzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. U. Drozdova, E. V. Daniels, A. V. Fokina | ||
| "... reference AMI only a small number of the patients received the main drug groups (antiplatelet agents, β ..." | ||
| Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
| O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
| "... and the antiplatelet agent – acetylsalicylic acid, are highlighted on the basis of the results of clinical studies ..." | ||
| Vol 10, No 3 (2014) | THE CAPABILITIES OF A REGISTER AS A QUALITY CONTROL OF THE PHARMACOTHERAPY IN OUTPATIENTS AT HIGH RISK OF CARDIOVASCULAR COMPLICATIONS (THE "LIS-1" REGISTER) | Abstract similar documents |
| M. L. Ginzburg, S. Y. Martsevich, N. P. Kutishenko, Y. V. Lukina, A. D. Deev | ||
| "... receiving b-blockers, 35.3% - renin-angiotensin-aldosterone system (RAAS) inhibitors, 15.7% - antiplatelet ..." | ||
| Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
| T. M. Uskach, A. S. Tereshchenko | ||
| "... Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment ..." | ||
| Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
| D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
| "... of antiplatelet therapy resistance is significantly higher in patients with diabetes mellitus and obesity (р<0 ..." | ||
| Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
| "... . In addition to endovascular treatment, dual antiplatelet therapy plays a key role in the treatment ..." | ||
| Vol 10, No 6 (2014) | CHANGES IN PREHOSPITAL PHARMACOTHERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN 2005-2014 ACCORDING TO THE LIS REGISTER | Abstract similar documents |
| S. Y. Martsevich, M. L. Ginzburg, N. P. Kutishenko, A. V. Zagrebelnyy, I. S. Balashov, L. G. Garkina | ||
| "... . The positive changes in the prescription of antiplatelet agents (13.5% in 2005 and 27.4% in 2014), statins (1 ..." | ||
| Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
| N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
| "... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and clopidogrel by optical aggregometry in patients ..." | ||
| Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
| L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
| Vol 10, No 6 (2014) | THE SIGNIFICANCE OF PLATELET FUNCTIONAL ACTIVITY TESTING IN THE PREVENTION OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS RECEIVING ANTIPLATELET THERAPY | Abstract similar documents |
| D. A. Andreev | ||
| "... complications in patients receiving antiplatelet therapy is presented. Indications for antiplatelet therapy ..." | ||
| Vol 16, No 6 (2020) | Actual Issues of Ischemic and Hemorrhagic Events Risk Management During Antithrombotic Therapy in Patients with Acute Coronary Syndrome | Abstract similar documents |
| R. M. Velieva, T. B. Pecherina, A. S. Vorobiev, V. V. Kashtalap, D. Yu. Sedykh | ||
| "... Today, optimal duration of double antiplatelet (DAPT) and triple antithrombotic therapy (TATT ..." | ||
| Vol 14, No 4 (2018) | Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke | Abstract similar documents |
| S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov | ||
| "... CYP17A1 is one of the many genes that can participate in the formation of predisposition ..." | ||
| Vol 13, No 6 (2017) | ASSESSMENT OF CHANGES IN QUALITY OF PREHOSPITAL TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME IN THE LAST FEW YEARS: LIS-1 VS LIS-3 REGISTRIES | Abstract similar documents |
| Yu. V. Semenova, A. V. Zagrebelnyy, N. P. Kutishenko, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... in the LIS-1 registry, more often took antiplatelet drugs (23.2% vs 15.7%, respectively; p<0.01) and statins ..." | ||
| Vol 14, No 2 (2018) | WHAT DO PATIENTS WITH ATRIAL FIBRILLATION KNOW ABOUT STROKE AND SYSTEMIC EMBOLISM PREVENTION? DATA OF THE PRIMA-TERRA REGISTRY | Abstract similar documents |
| R. М. Linchak, O. G. Kompaniyets, A. M. Nedbaykin | ||
| "... warfarin, 15% new oral anticoagulants (NOAC). The majority of patients received antiplatelet agents ..." | ||
| Vol 11, No 1 (2015) | ASPECTS OF LIPID-LOWERING THERAPY WITH ATORVASTATIN IN PATIENTS WITH MYOCARDIAL INFARCTION FROM THE PERSPECTIVE OF PERSONALIZED MEDICINE | Abstract similar documents |
| M. V. Solodun, S. S. Yakushin | ||
| Vol 17, No 5 (2021) | Genetic Polymorphism of beta1-adrenergic Receptors and the Effect on the Clinical Efficacy of beta-adrenoblockers | Abstract similar documents |
| V. N. Larina, M. V. Leonova | ||
| "... was a systematic analysis of scientific data from pharmacogenetic studies on the role of beta1-adrenergic receptor ..." | ||
| Vol 12, No 4 (2016) | Adherence to attendance at outpatient clinic, quality of prehospital therapy, and direct outcome of acute coronary syndrome: analysis within LIS-3 registry | Abstract similar documents |
| Yu. V. Semenova, N. P. Kutishenko, A. V. Zagebelnyy, A. D. Deev, M. L. Ginzburg, S. Yu. Martsevich | ||
| "... infarction as an outcome of ACS. Taking antiplatelet agents, beta-blockers and long-acting nitrates before ..." | ||
| Vol 14, No 6 (2018) | Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation | Abstract PDF (Eng) similar documents |
| A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee | ||
| "... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and clopidogrel was mostly ..." | ||
| Vol 17, No 6 (2021) | Prehospital Period in Patients with COVID-19: Cardiovascular Comorbidity and Pharmacotherapy During the First Epidemic Wave (Hospital Registry Data) | Abstract similar documents |
| S. Yu. Martsevich, M. M. Lukyanov, M. M. Pulin, N. P. Kutishenko, E. Yu. Andreenko, V. P. Voronina, V. A. Dindikova, N. A. Dmitrieva, A. V. Zagrebelnyy, O. V. Lerman, A. N. Makoveeva, E. Yu. Okshina, A. A. Smirnov, E. V. Kudryashov, I. V. Budaeva, E. S. Nikoshnova, O. E. Karpov, O. M. Drapkina | ||
| "... not receive antihypertensive therapy, a low proportion of patients receiving antiplatelet agents and statins ..." | ||
| Vol 12, No 2 (2016) | ATRIAL FIBRILLATION AND ISCHEMIC HEART DISEASE: HOW TO COMBINE ANTIPLATELET AND ANTICOAGULANT THERAPY, DEPENDING ON THE CLINICAL SITUATION? | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova, A. V. Rodionov | ||
| Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
| L. A. Haisheva, S. V. Shlyk | ||
| "... of revealed disorders with antiplatelet agent — clopidogrel 75 mg/day. Material and methods. 40 patients ..." | ||
| Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
| O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
| "... and induced flow cytofluorometry during antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA ..." | ||
| Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
| V. A. Sulimov, E. V. Moroz | ||
| "... of cardiovascular complications and activity of platelet aggregation, to assess safety of dual antiplatelet therapy ..." | ||
| Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
| N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
| "... Aim. To compare antiplatelet effect of two acetylsalicylic acid medicines, Acecardol ("Synthesis ..." | ||
| Vol 15, No 5 (2019) | Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry | Abstract similar documents |
| Z. G. Tatarintseva, E. D. Kosmacheva, S. V. Kruchinova, V. A. Akinshina, A. A. Khalafyan | ||
| "... of Cardiology (ESC), patients with coexisting AF and ACS should receive dual antiplatelet therapy ..." | ||
| Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
| A. V. Panov | ||
| "... therapy (TAT), selection of P2Y12 inhibitor, choice of oral anticoagulant to be combined with antiplatelet ..." | ||
| Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
| S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
| "... in angioplasty with stenting were found. Patients before ACS in 2014 received less antiplatelet agents than ..." | ||
| Vol 12, No 4 (2016) | The use of oral anticoagulants in patients with atrial fibrillation: cohort study data | Abstract similar documents |
| O. V. Gaisenok, A. S. Leonov | ||
| "... . Results. The rate of OAC use was 46.5% (warfarin – 22.4%, NOAC – 20.7%), antiplatelet agents use – 60 ..." | ||
| Vol 8, No 5 (2012) | THE LIS STUDY (LYUBERTSY STUDY OF MORTALITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION). EVALUATION OF THE PHARMACOTHERAPY. PART 1. TREATMENT OF PATIENTS BEFORE MYOCARDIAL INFARCTION AND ITS INFLUENCE ON HOSPITAL MORTALITY RATE | Abstract similar documents |
| S. Y. Marcevich, M. L. Ginzburg, N. P. Kutishenko, A. D. Deev, V. P. Smirnov, L. Y. Drozdova, E. V. Danijel's, A. V. Fokina | ||
| "... -blockers, 35.3% — ACE inhibitors, 15.7% — antiplatelet drugs, 1.9% — statins. Reduction in the hospital ..." | ||
| Vol 18, No 6 (2022) | Perioperative Management of Patients Receiving Antithrombotic Therapy in Schemes and Algorithms | Abstract similar documents |
| O. N. Dzhioeva, E. A. Rogozhkina, O. M. Drapkina | ||
| "... of antiplatelet and/or anticoagulant drugs is a complicating factor in invasive and surgical procedures ..." | ||
| Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
| V. N. Drozdov, V. A. Kim | ||
| "... Data about efficacy and safety of acetylsalicylic acid usage as antiplatelet drug and for cancer ..." | ||
| Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
| N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
| Vol 9, No 5 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER (PART 2) | Abstract similar documents |
| S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , in rational pharmacotherapy in cardiology was shown on the example of its substrates – digoxin, antiplatelet ..." | ||
| Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
| N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
| Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
| S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
| "... in patients with stable angina significantly increased: antiplatelets – up to 82.7%, beta-blockers – up to 74 ..." | ||
| Vol 14, No 2 (2018) | New Possibilities of Antithrombotic Therapy of Patients with Peripheral and Widespread Atherosclerotic Lesion | Abstract similar documents |
| A. L. Komarov, Е. S. Novikova, E. V. Guskova, Е. B. Yarovaya, A. N. Samko, E. Р. Panchenko | ||
| "... efficiency of present antiplatelet and anticoagulant drugs is shown in the key of preventing PAD thrombotic ..." | ||
| Vol 19, No 6 (2023) | Platelet phenotypes and practical aspects of platelet function testing in cardiology | Abstract similar documents |
| Zh. D. Kobalava, A. S. Pisaryuk, A. A. Filkova, E. S. Tukhsanboev, A. A. Boldyreva, D. P. Lazutova, I. A. Meray, M. A. Panteleev | ||
| "... the various consensus papers on assessing thrombotic and bleeding risk, monitoring antiplatelet therapy ..." | ||
| Vol 12, No 5 (2016) | Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms | Abstract PDF (Eng) similar documents |
| Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev | ||
| "... Aim. To evaluate treatment adherence and prevalence of CYP2C9 and VKORC1 gene mutations ..." | ||
| 1 - 100 of 168 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
